News Sentiment

CNTB sentiment intelligence

Connect Biopharma Holdings Ltd news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 61 Balanced news tone 58 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.38 Week of 17 Jul 2026
Weighted tone 61/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

73/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-5.2% over one week, +19.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Lake Street Maintains Connect Biopharma(CNTB.US) With Buy Rating, Maintains Target Price $9

Market Reaction

Price moving ahead of tone

69/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 73/100 classification
One-week reaction -5.2% Price reacting lower
Trend fit Trend inactive 19.0% over four weeks
Fair value 2.7% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 26
Neutral 31
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 7
Stock Titan 7
GlobeNewswire 5
Moomoo 4
Investing.com 4
TradingKey 4
marketscreener.com 3
TradingView 3

Event Lens

What the news is about

Classified themes
Market update 20
Earnings 15
Analyst action 12
Balance sheet 4
Guidance 4
Capital return 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 58
Investing.com Direct company coverage

Oppenheimer initiates Connect Biopharma stock with outperform rating

Oppenheimer has initiated coverage on Connect Biopharma (NASDAQ: CNTB) with an Outperform rating and an $8.00 price target, citing the company's lead drug rademikibart for inflammatory respiratory diseases. The drug, a next-generation human IgG4 anti-IL-4Rα antibody, is currently

Tone
Positive 82/100
Event
Analyst action
Published
09 Jul 2026 13:40
Source
Investing.com
Investing.com Nigeria Direct company coverage

Oppenheimer initiates Connect Biopharma stock with outperform rating By Investing.com

Oppenheimer has initiated coverage on Connect Biopharma Holdings Ltd (NASDAQ: CNTB) with an Outperform rating and an $8.00 price target. The company is developing rademikibart for inflammatory respiratory diseases, with Phase 2 trial results for asthma and COPD expected in the se

Tone
Positive 71/100
Event
Analyst action
Published
09 Jul 2026 13:10
Source
Investing.com Nigeria
Finviz Direct company coverage

CNTB - Connect Biopharma Holdings Ltd Dividends

This page provides detailed financial information for Connect Biopharma Holdings Ltd (CNTB), including dividend data, key financial ratios, performance metrics, and insider/institutional ownership. The company's last close was $2.36, experiencing a 4.07% decrease. It also shows v

Tone
Neutral 50/100
Event
Capital return
Published
06 Jul 2026 00:39
Source
Finviz
Finviz Direct company coverage

CNTB - Connect Biopharma Holdings Ltd Latest SEC Filings

This article provides the latest SEC filing information for Connect Biopharma Holdings Ltd (CNTB), alongside comprehensive financial data and performance metrics. It includes details such as market capitalization, income, sales, various financial ratios, insider and institutional

Tone
Neutral 50/100
Event
Market update
Published
04 Jul 2026 09:40
Source
Finviz
Investing.com UK Direct company coverage

Form 4 Connect Biopharma Holdings Ltd For: 1 July By Investing.com

This article provides details about a Form 4 filing for Connect Biopharma Holdings Ltd, dated July 1st. It highlights the stock symbol CNTB and its performance, showing a 2.93% increase. The piece is brief and primarily serves as a notification of the filing.

Tone
Positive 61/100
Event
Market update
Published
02 Jul 2026 11:39
Source
Investing.com UK
Stock Titan Direct company coverage

Connect Biopharma (CNTB) director granted 3,738 fully vested shares as fees

Connect Biopharma Holdings Ltd director Dr. Kleanthis Gabriel Xanthopoulos was granted 3,738 fully vested Ordinary Shares on June 30, 2026. These shares were issued in lieu of a portion of his 2026 annual board cash retainers for service during Q2 2026. Following this award, Dr.

Tone
Neutral 50/100
Event
Balance sheet
Published
01 Jul 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Connect Biopharma (NASDAQ: CNTB) director receives 6,718-share award as 2026 board compensation

Connect Biopharma (NASDAQ: CNTB) director Jean I. Liu was granted 6,718 ordinary shares as compensation for her 2026 annual board service during Q2 2026, in lieu of cash retainers. This award, calculated based on the average closing share price for 30 days preceding June 30, 2026

Tone
Neutral 50/100
Event
Balance sheet
Published
01 Jul 2026 20:39
Source
Stock Titan
www.marketscreener.com Direct company coverage

Connect Biopharma Holdings Limited(NasdaqGM: CNTB) added to Russell Microcap Index

Connect Biopharma Holdings Limited (NasdaqGM: CNTB) has been added to the Russell Microcap Index. This follows a previous announcement that the company was also added to the Russell 3000E Growth Benchmark. The news highlights the company's progress and increased visibility within

Tone
Positive 81/100
Event
Market update
Published
29 Jun 2026 05:39
Source
www.marketscreener.com
Investing.com Canada Direct company coverage

Piper Sandler initiates Connect Biopharma stock with overweight rating By Investing.com

Piper Sandler initiated coverage on Connect Biopharma Holdings Ltd (NASDAQ:CNTB) with an Overweight rating and a $7.00 price target. The firm highlighted rademikibart's potential as a unique biologic for acute asthma and COPD exacerbations, expecting significant sales growth and

Tone
Positive 70/100
Event
Analyst action
Published
26 Jun 2026 09:09
Source
Investing.com Canada
TradingView Direct company coverage

Connect Biopharma Holdings Ltd. Actuals & Estimates (NASDAQ:CNTB)

This article provides an overview of Connect Biopharma Holdings Limited (NASDAQ: CNTB) stock, including its current price, market capitalization, historical performance, and analyst forecasts. It details financial data such as earnings per share, revenue, net income, and EBITDA,

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:09
Source
TradingView
Investing.com Direct company coverage

H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7

H.C. Wainwright has reiterated a Buy rating for Connect Biopharma Holdings Ltd (NASDAQ:CNTB) with a $7.00 price target, though InvestingPro data suggests the stock is currently overvalued. The company is actively progressing with its Phase 2 Seabreeze STAT Asthma and COPD studies

Tone
Positive 73/100
Event
Analyst action
Published
25 Jun 2026 11:40
Source
Investing.com
TradingKey Direct company coverage

Connect Biopharma Holdings Ltd (CNTB) Valuation: PE, PB & Fair Value Analysis

Connect Biopharma Holdings Ltd (CNTB) currently holds a valuation score of 6.10, ranking 355 out of 387 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -1.79, indicating it is -34.93% below its recent high and -131.62% above its recent low. Key

Tone
Neutral 50/100
Event
Market update
Published
24 Jun 2026 07:42
Source
TradingKey
TradingKey Direct company coverage

Connect Biopharma Holdings Ltd (CNTB) Earnings Forecast: Future EPS & Revenue Growth Estimates

Connect Biopharma Holdings Ltd (CNTB) has an earnings forecast score of 8.67, ranking 71st in the Biotechnology & Medical Research industry, with an average price target of $7.50. Analysts, based on 7 ratings, largely recommend a "Buy" for the stock, forecasting an expected reven

Tone
Positive 72/100
Event
Earnings
Published
23 Jun 2026 07:42
Source
TradingKey
Investing.com India Direct company coverage

H.C. Wainwright reiterates Buy on Connect Biopharma stock at $7 By Investing.com

H.C. Wainwright has reiterated a Buy rating and a $7.00 price target for Connect Biopharma Holdings Ltd (NASDAQ:CNTB), noting a significant upside potential from its current trading price of $2.08. The firm highlighted that enrollment for the Phase 2 Seabreeze STAT COPD study is

Tone
Positive 74/100
Event
Analyst action
Published
18 Jun 2026 17:09
Source
Investing.com India
TradingKey Direct company coverage

Connect Biopharma Holdings Ltd (CNTB) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Connect Biopharma Holdings Ltd (CNTB), listing its major shareholders and their respective proportions. It also breaks down shareholder types by category, such as venture capital and corporations. Additionally, the report provides

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 09:39
Source
TradingKey
TradingKey Direct company coverage

Connect Biopharma Holdings Ltd (CNTB) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for Connect Biopharma Holdings Ltd (CNTB). It states that the company has distributed $0.00 in dividends over the past five years and shows no historical data for stock splits. The stock's current price and mar

Tone
Neutral 50/100
Event
Capital return
Published
17 Jun 2026 21:11
Source
TradingKey
Investing.com Nigeria Direct company coverage

Connect Biopharma stock rises after Phase 2 asthma study enrollment By Investing.com

Connect Biopharma Holdings Ltd (NASDAQ: CNTB) shares rose 8% after announcing the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study for rademikibart. The company expects to report topline data from this study in early September 2026, followed by results from its

Tone
Positive 77/100
Event
Earnings
Published
17 Jun 2026 15:26
Source
Investing.com Nigeria
Investing.com Direct company coverage

Connect Biopharma completes asthma trial enrollment

Connect Biopharma Holdings Limited has completed enrollment for its Phase 2 Seabreeze STAT Asthma study, evaluating rademikibart for acute asthma exacerbations. The company expects to release topline data from the asthma study in early September 2026 and plans to meet with the FD

Tone
Positive 70/100
Event
Guidance
Published
17 Jun 2026 14:11
Source
Investing.com
Quiver Quantitative Direct company coverage

Connect Biopharma Completes Enrollment in Phase 2 Seabreeze STAT Asthma Study and Anticipates Upcoming COPD Study Data

Connect Biopharma Holdings Limited has completed enrollment in its Phase 2 Seabreeze STAT Asthma study for rademikibart, a next-generation antibody for asthma exacerbations. The company expects to report topline results from the asthma study by early September 2026, with data fro

Tone
Positive 64/100
Event
Earnings
Published
17 Jun 2026 13:12
Source
Quiver Quantitative